New vaccine design based on defective genomes that combines features of attenuated and inactivated vaccines.
BACKGROUND
New vaccine designs are needed to control diseases associated with antigenically variable RNA viruses. Foot-and-mouth disease (FMD) is a highly contagious disease of livestock that inflicts severe economic losses. Although the current whole-virus chemically inactivated vaccine has proven effective, it has led to new outbreaks of FMD because of incomplete inactivation of the virus or the escape of infectious virus from vaccine production premises. We have previously shown that serial passages of FMD virus (FMDV) C-S8c1 at high multiplicity of infection in cell culture resulted in virus populations consisting of defective genomes that are infectious by complementation (termed C-S8p260).


RESULTS
Here we evaluate the immunogenicity of C-S8p260, first in a mouse model system to establish a proof of principle, and second, in swine, the natural host of FMDV C-S8c1. Mice were completely protected against a lethal challenge with FMDV C-S8c1, after vaccination with a single dose of C-S8p260. Pigs immunized with different C-S8p260 doses and challenged with FMDV C-S8c1 either did not develop any clinical signs or showed delayed and mild disease symptoms. C-S8p260 induced high titers of both FMDV-specific, neutralizing antibodies and activated FMDV-specific T cells in swine, that correlated with solid protection against FMDV.


CONCLUSIONS
The defective virus-based vaccine did not produce detectable levels of transmissible FMDV. Therefore, a segmented, replication-competent form of a virus, such as FMDV C-S8p260, can provide the basis of a new generation of attenuated antiviral vaccines with two safety barriers. The design can be extended to any viral pathogen that encodes trans-acting gene products, allowing complementation between replication-competent, defective forms.
Rodríguez-Calvo
Teresa
T
Centro de Investigación en Sanidad Animal, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, Madrid, Spain.
Ojosnegros
Samuel
S
Sanz-Ramos
Marta
M
García-Arriaza
Juan
J
Escarmís
Cristina
C
Domingo
Esteban
E
Sevilla
Noemí
N
D000818:Animals; D057134:Antibodies, Neutralizing; D005536:Foot-and-Mouth Disease / Q000628:therapy*; D029544:Foot-and-Mouth Disease Virus; D016679:Genome, Viral; D051379:Mice; D012692:Serial Passage; D013552:Swine; D013601:T-Lymphocytes / Q000276:immunology; D016896:Treatment Outcome; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated; D014765:Viral Vaccines
D057134:Antibodies, Neutralizing; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated; D014765:Viral Vaccines
J Virol. 1997 Apr;71(4):2606-14
9060612
Vaccine. 1998 Oct;16(16):1516-22
9711798
J Virol. 2003 Jan;77(2):1621-5
12502879
J Virol. 2004 Apr;78(7):3319-24
15016853
J Virol. 2005 Oct;79(20):12623-34
16188964
Vaccine. 2007 Jan 22;25(6):1043-54
17157418
Virology. 1983 Jul 30;128(2):310-8
6310859
J Virol. 1993 Dec;67(12):6917-21
8230412
Virus Res. 2003 Jan;91(1):47-63
12527437
Vaccine. 1990 Aug;8(4):299-303
2204242
Am J Vet Res. 1968 Mar;29(3):693-701
4295430
Arch Virol. 1975;47(1):47-56
167679
J Virol. 2000 Sep;74(18):8316-23
10954530
J Virol. 2004 Nov;78(21):11678-85
15479809
J Gen Virol. 2000 Jul;81(Pt 7):1699-702
10859374
Virology. 2005 May 10;335(2):155-64
15840515
Vaccine. 1991 May;9(5):319-25
1872015
Virology. 1988 Nov;167(1):113-24
2460992
Virus Res. 2003 Jan;91(1):81-99
12527439
Nature. 1981 Feb 12;289(5798):555-9
6258084
Curr Top Microbiol Immunol. 2009;329:129-62
19198565
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3473-8
19208813
Proc Natl Acad Sci U S A. 1989 Aug;86(15):5883-7
2474821
Dev Biol (Basel). 2004;119:449-55
15742659
J Virol. 1987 May;61(5):1621-9
3033288
J Virol. 2007 Oct;81(19):10597-605
17634218
Rev Sci Tech. 2002 Dec;21(3):675-87
12523706
Virus Res. 1990 Dec;18(1):3-7
1964520
Rev Sci Tech. 2002 Dec;21(3):711-21
12523709
Virology. 1997 Jan 6;227(1):96-102
9007062
J Immunol. 1991 Jan 15;146(2):749-55
1702816
Adv Virus Res. 1999;53:111-26
10582097
Vet J. 2005 Mar;169(2):197-209
15727911
Virus Res. 1987 Sep;8(3):261-74
2446442
J Virol. 2003 Jan;77(2):1219-26
12502839
J Virol. 2008 Nov;82(21):10465-76
18715925
J Virol. 1992 Apr;66(4):1835-40
1312607
Br Vet J. 1993 May-Jun;149(3):207-23
8392891
Nature. 1985 Apr 11-17;314(6011):548-50
2986004
Virus Res. 2003 Jan;91(1):9-32
12527435
Virology. 2005 Feb 5;332(1):384-96
15661169
Nat Rev Microbiol. 2004 Jun;2(6):473-82
15152203
Science. 1981 Dec 4;214(4525):1125-9
6272395
Curr Top Microbiol Immunol. 2006;299:51-82
16568896
J Mol Biol. 2006 Jul 14;360(3):558-72
16797586
J Hyg (Lond). 1983 Oct;91(2):329-34
6315814
Epidemiol Infect. 1996 Oct;117(2):349-60
8870633
Vaccine. 2007 Apr 20;25(16):2974-83
17303293
Vaccine. 2003 Dec 12;22(2):268-79
14615155
Virus Res. 1998 Aug;56(2):125-33
9783461
Annu Rev Microbiol. 1997;51:151-78
9343347
Vaccine. 2009 May 26;27(25-26):3299-305
19200842